# TrueSight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/truesight

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.truesight.com
- Total disclosed funding: $16M
- Latest round: Series B (Sep 1, 2021)
- Investors on record: 6

## About

Established in 2018 and based in Beijing, Chian, Hubei Jingzhen Medical Technology Co., Ltd., trading as TrueSight, operates as a digital precision surgery technology solution provider that focuses on medical image artificial intelligence research. The company cooperates with Qinghua University School Of Medicine, Xidian University and Zhongnan Hospital Of Wuhan University. In February 2026, TrueSight raised a series B+ funding from new investor Wuhan Wuchuangyuan Investment.
The company provides medical intelligent image technology solutions for medical industry and patients. The product of the company includes TrueSight, TrueView, TrueTrace and new coronary pneumonia AI intelligent clinical aided analysis system. The company adopts artificial intelligence algorithm.
The company's revenue is generated by providing digital precision surgery technology solution and automated 3D liver reconstruction systems.
The company will use the series B+ funding to further promote its research and application in the field of medical intelligent imaging technology.

## Funding rounds

- Series B, Sep 1, 2021, $16M — Y&R Capital, Qirong Venture Capital
- Series A, Sep 25, 2020 — Plum Ventures
- Angel, Feb 13, 2020 — ZhenFund, Y&R Capital, Changfeng Hengchuang Venture, Turing Capital

## Investors

- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Angel
- Y&R Capital (https://capitalatlas.ai/funds/y-r-capital) — Angel, Series B
- Changfeng Hengchuang Venture (https://capitalatlas.ai/funds/changfeng-hengchuang-venture) — Angel
- Turing Capital (https://capitalatlas.ai/funds/turing-capital) — Angel
- Plum Ventures (https://capitalatlas.ai/funds/plum-ventures) — Series A
- Qirong Venture Capital (https://capitalatlas.ai/funds/qirong-venture-capital) — Series B